. Author manuscript; available in PMC: 2022 Oct 29.

Published in final edited form as: Expert Rev Mol Med. 2022 Jan 28;24:e7. doi: 10.1017/erm.2021.32

Table 1.

CAR-Ts approved for treating haematological cancers

Trade Name	KYMRIAH	YESCARTA	TECARTUS	BREYANZI	ABECMA	ARI-0001	Relma-cel
proper name	tisagenlecleucel	axicabtagene ciloleucel	brexucabtagene autoleucel	lisocabtagene maraleucel	idecabtagene vicleucel		Relmacabtagene Autoleucel
T cell sources	autologous T cells	autologous T cells	autologous T cells	autologous CD4+,CD8+	autologous T cell	autologous T cell	autologous CD4+ and CD8+
Year approved	30 August 2017	18 October 2017	23 July 2020	5 February 2021	26 March 2021	10 February 2021	6 September 2021
Approved by	FDA	FDA	FDA	FDA	FDA	AEMPS	NMPA
ScFv (Ab)	FMC63	FMC63	FMC63	FMC63	Murine	A3B1 murine	FMC63
Linker Virus	(GGGGS)3 Lentivirus	(GGGGS)3 Retrovirus	(GGGGS)3 Retrovirus	Lentivirus	Lentivirus	Lentivirus	Lentivirus
Promoter	EF1a	MSCV	MSCV	?	MND	EF1a
Target	CD19	CD19	CD19	CD19	BCMA	CD19	CD19
Disease	(R/R) B-ALL, DLBCL, etc.	DLBCL, etc.	(R/R) MCL	(R/R) LBCL, DLBCL, etc.	(R/R) multiple myeloma	(R/R) ALL	(R/R) LBCL
H/T domain	CD8a	CD28	CD28	IgG4 (H), CD28 (TM)	CD8a	CD8a
Signalling domain	4–1BB, CD3ζ	CD28, CD3ζ	CD28, CD3ζ	4–1BB, CD3ζ	4–1BB, CD3ζ	4–1BB, CD3ζ	4–1BB, CD3ζ
Other factor Generation	2nd	2^nd	T cell enrichment 2nd	EGFRt 2nd	2nd	2nd	EGFRt 2nd
Company	Novartis	Kite Pharma	Kite Pharma	Juno Therapeutics	BMS	Hospital clinic (spain)	JW Therapeutics

FDA, U.S. Food and Drug Administration; AEMPS, The Spanish Agency of Medicines and Medical Devices; NMPA, the National Medical Products Administration of China.